August 2023

Latest Advancements in Antibody Engineering – Bispecifics, Diagnostic Controls, and More

2024-04-24T10:35:04-04:00August 29th, 2023|Webinars|

In this webinar, you will learn: Antibody technologies for the design of unique antibody formats Advancements in engineering efforts for the development of functionally tailored antibodies, recombinant isotype antibody panels, and multivalent fragment antibody constructs Characterization of different bispecific antibody formats Next generation protein sequencing to aid in bispecific antibody design [...]

May 2023

Rational Antibody Design and Engineering with Next Generation Protein Sequencing

2024-04-29T13:20:11-04:00May 9th, 2023|Webinars|

In this webinar, you will learn: A strategy for generating recombinant mAbs and antibody derivatives directed towards antigens involved in mitotic cell division Methods for antibody engineering and customization, species switching, and construction of antibody fragments How Next Generation Protein Sequencing (NGPS) works Applications of NGPS to aid engineering and recombinant production of [...]

Secure Full Antibody and Target IP Protection with Next Generation Protein Sequencing

2024-04-01T15:46:27-04:00May 3rd, 2023|Articles|

Written by: Genya Gorshtein, MSc Published: April 21, 2023 Contents Introduction Target Specification for First Generation Antibodies Patent Strategies for Second-Generation Antibodies Next Generation Protein Sequencing and Proteomics Strengthens IP Protections Introduction Intellectual property (IP) protection is a critical step during the commercialization of antibodies [...]

February 2023

Therapeutic Antibody Discovery: From Target to Candidate

2024-12-03T13:57:42-05:00February 24th, 2023|Articles|

Written by: Genya Gorshtein, MSc Published: February 17, 2023 Contents The Drug Development Pathway Target Discovery and Validation Antibody Discovery Characterization and Lead Selection Engineering and Optimization Candidate Selection Therapeutic Antibody Discovery with Rapid Novor The Drug Development Pathway The four phases in the drug [...]

December 2022

The Hunt for Novel Therapeutics Through Antibody Engineering

2023-06-21T10:25:09-04:00December 2nd, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: November 1, 2022 Contents Introduction Approaches for Engineering Antibody Therapeutics Driving Antibody Engineering with Next Generation Protein Sequencing and Proteomics Introduction Antibody engineering encompasses various development, production strategies, and modification techniques to improve the biological properties of monoclonal antibodies (mAbs) [...]

Cell Specific Protein Degradation with Antibody Conjugated PROTACs

2023-05-25T10:29:24-04:00December 2nd, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: November 25, 2022 Contents Introduction General PROTAC Structure and Function Antibody-Conjugated PROTACs Developing AbPROTACs with De Novo Antibody Sequencing and Proteomics Introduction Small-molecule drug development is aimed at inhibiting disease-promoting protein function through occupancy-driven protein inhibition. A major caveat of [...]

September 2022

Antibody-Drug Conjugates as Anti-Cancer Therapeutics

2024-01-22T13:13:13-05:00September 19th, 2022|Articles|

Written by: Genya Gorshtein, MSc Published: September 14, 2022 Contents Introduction ADCs as Novel Anti-Cancer Chemotherapeutics Key Components of ADCs Future Generation of ADCs De Novo Protein Sequencing Applications in ADC Development Introduction An antibody-drug conjugate (ADC) is a monoclonal antibody (mAb) with a covalently attached [...]

March 2022

September 2021

Monoclonal vs Polyclonal Antibody Drugs

2024-12-03T11:21:15-05:00September 8th, 2021|Articles|

The transition from polyclonal antibody drugs to a more targeted monoclonal approach was made possible through a series of scientific and technological advancements; the most notable of which is the hybridoma technique developed by Köhler and Milstein, which allowed the generation of pure antibodies at scale.

August 2021

Antibody Validation and its Use Cases

2024-04-29T13:22:17-04:00August 4th, 2021|Articles|

Antibodies are used in a variety of ways in academia and industry, from tools to therapeutics. Because antibodies are produced using live processes, which are naturally error-prone, validation is required from time to time. Furthermore, to develop biological therapeutics, the protein sequence must be confirmed as part of the regulatory process.

June 2021

Bispecific Therapeutics Explained

2024-12-03T11:54:39-05:00June 28th, 2021|Articles|

Bispecific therapeutics are monoclonal antibodies that carry a specific antigen-binding capability on each arm. Bispecifics are thus capable of having two specificities that can either double the binding affinity of the antibody toward the same antigen (increased avidity), or can now bind to two targets. Bispecifics are most often described as two types: trispecifics and bispecific T-cell engaged antibodies (BiTE).

Major Antibody Databases and Their Applications

2024-12-03T11:58:36-05:00June 18th, 2021|Articles|

Written by María Gerpe, PhD June 18, 2021 Introduction Research publications represent an additional source of validation proof for commercially available antibodies. As such, academic and industry scientists often also rely on publication references to decide which commercial antibody to purchase. Several independent efforts exist to compile such information. For instance, [...]

March 2021

November 2020

September 2020

June 2016

Moving Towards Recombinant Monoclonal Antibodies

2023-05-15T11:59:37-04:00June 30th, 2016|Articles|

Recombinant Monoclonal Antibodies (rAbs) are highly reproducible, customizable and pure alternatives to the traditional antibodies produced by hybridomas. Get the antibody protein sequence, either by DNA sequencing or the de novo protein sequencing technology, you can rest assured that you can have the exact antibody made recombinantly anytime in the future.